Intragenic antagonistic roles of protein and circRNA in tumorigenesis

Jlenia Guarnerio1,2, Yang Zhang1, Giulia Cheloni1

  • 1Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.

Cell Research
|June 19, 2019
PubMed

Insights

A novel circular RNA, circPOK, acts as a cancer-promoting oncogene, distinct from its tumor-suppressing linear counterpart. This discovery reveals a new regulatory unit, the iRegulon, with opposing functions in cancer.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • Circular RNAs (circRNAs) are emerging regulators in cancer development.
  • The Zbtb7a gene produces both linear (Pokemon protein) and circular (circPOK) RNA transcripts.
  • Aberrant circRNA expression is linked to various pathologies, including cancer.

Purpose of the Study:

  • To characterize the novel circRNA, circPOK, derived from the Zbtb7a gene.
  • To elucidate the distinct functions of circPOK and its linear counterpart in mesenchymal tumors.
  • To identify novel regulatory mechanisms in cancer pathogenesis.

Main Methods:

  • RNA sequencing and bioinformatics analysis to identify and characterize circPOK.
  • Functional assays to determine the oncogenic role of circPOK.
  • Investigation of circPOK's interaction with the ILF2/3 complex.
  • Analysis of Pokemon protein and circPOK expression in cancer tissues.

Main Results:

  • circPOK functions as a non-coding RNA with proto-oncogenic activity in mesenchymal tumors.
  • circPOK promotes proliferation and angiogenesis by co-activating the ILF2/3 complex.
  • Pokemon protein, encoded by the linear transcript, acts as a tumor suppressor.
  • Expression of Pokemon protein and circPOK is uncoupled in cancer due to differential post-transcriptional regulation.

Conclusions:

  • A novel genetic unit, the iRegulon, generates distinct circular and linear RNA products with opposing functions.
  • circPOK represents a new class of oncogenic circRNAs.
  • Aberrant expression of iRegulons contributes to disease pathogenesis, highlighting new therapeutic targets.

Related Concept Videos

Role of Proteins in the Human Body01:28

Role of Proteins in the Human Body

Proteins are the building block of life. They are also  the most abundant macromolecules with as many diverse roles in the body. They are part of many structural components that provide unique shapes and structures to animal cells, tissues, and organs. In addition, they also act as biological catalysts and carry out several anabolic and catabolic reactions. Notably, some proteins are chemical messengers and regulate many critical processes, such as metabolism, growth, and development. They...
6.2K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
921
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.4K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
920